Literature DB >> 7882359

Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.

J Pressacco1, B Mitrovski, C Erlichman, D W Hedley.   

Abstract

The effects of de novo dTMP inhibition by N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2- thenoyl)-L-glutamic acid (D1694) or N6-[4-(morpholinosulfonyl)benz]-N6-diaminobenz[cd]indole glucuronate (AG-331) on clonogenic survival, thymidylate synthase (TS) and thymidine kinase (TK) activity, and expression of S-(p-nitrobenzyl)-6-thioinosine-sensitive nucleoside transporter (NT) sites were addressed in the human bladder cancer cell line, MGH-U1. These two TS inhibitors are structurally diverse. D1694 is a folate-based TS inhibitor, whereas AG-331 is a novel agent that inhibits the cofactor binding site of the enzyme. They also differ with respect to their cytotoxic effects in this cell line; D1694 cytotoxic 50% inhibitory concentration (IC50) and IC90 were 6.0 and 9.0 nM, respectively and IC50 and IC90 for TS inhibition were 2.5 and 4.8 nM, respectively. In contrast, AG-331 cytotoxic IC50 could not be achieved even at concentrations of up to 20 microM for 24-h exposures, and IC50 and IC90 for TS inhibition were 0.7 and 3.0 microM, respectively. Similar effects for D1694 and AG-331 were observed in their modulation of TK activity and NT expression. 5-(SAENTA-x8)-Fluorescein, a highly modified form of adenosine incorporating a fluorescein molecule which binds with a 1:1 stoichiometry to S-(p-nitrobenzyl)-6-thioinosine-sensitive NT sites, was used to investigate the expression of NT following exposure of cells to D1694 and AG-331. TK activity was addressed by the metabolism of [3H]thymidine to [3H]TMP by cellular extracted protein and by an alternative flow cytometric method using a modified form of thymidine incorporating a fluorescent molecule, dansyl-5-amino-2-deoxyuridine. Results obtained by both methods were comparable. At concentrations of 5 and 10 nM, D1694 increased TK activity 2.3-4.5-fold and NT expression 34-39-fold. AG-331, at concentrations of 5 and 10 microM, increased TK activity 1.8-2.5-fold and NT expression 22-31-fold, respectively. These data suggest that TK activity and NT expression have a common regulatory mechanism which is sensitive to endogenous dTTP pools and that the salvage pathway is a complex system of kinases coordinated with transport of nucleosides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882359

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Novel 99mTc-labelled complexes with thymidine isocyanide: radiosynthesis and evaluation as potential tumor imaging tracers.

Authors:  Xiaojiang Duan; Xuran Zhang; Qianqian Gan; Si'an Fang; Qing Ruan; Xiaoqing Song; Junbo Zhang
Journal:  Medchemcomm       Date:  2018-03-06       Impact factor: 3.597

Review 2.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

3.  Molecular predictors of gemcitabine response in pancreatic cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

Review 4.  Imaging biomarkers in primary brain tumours.

Authors:  Egesta Lopci; Ciro Franzese; Marco Grimaldi; Paolo Andrea Zucali; Pierina Navarria; Matteo Simonelli; Lorenzo Bello; Marta Scorsetti; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-18       Impact factor: 9.236

5.  Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.

Authors:  Bunzo Nakata; Ryosuke Amano; Shigetomi Nakao; Tatsuro Tamura; Osamu Shinto; Toshiki Hirakawa; Yoshihiro Okita; Nobuya Yamada; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-02-24

Review 6.  Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling.

Authors:  M Pastor-Anglada; E Errasti-Murugarren; I Aymerich; F J Casado
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

7.  The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells.

Authors:  David A Plotnik; Lena J McLaughlin; Kenneth A Krohn; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2012-05-05       Impact factor: 2.408

8.  Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.

Authors:  S W Pridgeon; R Heer; G A Taylor; D R Newell; K O'Toole; M Robinson; Y-Z Xu; P Karran; A V Boddy
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

9.  Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Authors:  Aurélie Courtin; Frances M Richards; Tashinga E Bapiro; Jo L Bramhall; Albrecht Neesse; Natalie Cook; Ben-Fillippo Krippendorff; David A Tuveson; Duncan I Jodrell
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

10.  Membrane drug transporters and chemoresistance in human pancreatic carcinoma.

Authors:  Wolfgang Hagmann; Ralf Faissner; Martina Schnölzer; Matthias Löhr; Ralf Jesnowski
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.